Product development studies of amino acid conjugate of aceclofenac

Current Drug Delivery

Volumn 6, Issue 2, 2009, Pages 208-216

  Singh, Ajay Pal ^a   Ramadan, Wafa Mossa ^a   Dahiya, Rajiv ^b   Sarpal, A S ^c   Pathak, Kamla ^b  

^a AL ARAB MEDICAL UNIVERSITY   (Libyan Arab Jamahiriya)

^b Rajiv Academy for Pharmacy   (India)

^c INDIAN OIL CORPORATION LIMITED   (India)

Author keywords

Aceclofenac; Amino acid conjugate; Product development

Indexed keywords

ACECLOFENAC; DICYCLOHEXYLCARBODIIMIDE; PHENYLALANINE METHYL ESTER;

ACIDITY; ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG CONJUGATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; FEMALE; IONIC STRENGTH; LIPOPHILICITY; MALE; NONHUMAN; PARTICLE SIZE; PARTITION COEFFICIENT; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STOMACH PH; TEMPERATURE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, THIN LAYER; CRYSTALLOGRAPHY; DICLOFENAC; FEMALE; HYDROGEN-ION CONCENTRATION; HYDROPHOBICITY; MALE; MASS SPECTROMETRY; PARTICLE SIZE; PHENYLALANINE; PRODRUGS; RATS; RATS, INBRED STRAINS; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STOMACH; TRANSITION TEMPERATURE; X-RAY DIFFRACTION;

EID: 66749137644     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720109787846261     Document Type: Article

References (22)

1. Michael, J.H.; Dhiren, R.T.; James, L.S.; Ronald, T.; Borchardt, E.H.K. In Biotechnology: Pharmaceutical Aspects; Optimizing the "Drug-Like" Properties of Leads in Drug Discovery; Springer-Verlag: New York, 2007, Vol. 4, pp. 99- 130.
2. Breitenbach, J. Melt extrusion: from process to drug delivery technology. Eur. J. Pharm. Biopharm., 2002, 54, 2, 107-17.
3. Serajuddin, A.T.M. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci., 1999, 88, 1058-66.
4. Merisko-Liversidge, E.; Sarpotdar, P.; Bruno, J.; Hajj, S.; Wei L.; Peltier, N.; Rake J.; Shaw, J.M.; Pugh, S.; Polin, L.; Jones, J.; Corbett, T.; Cooper, E.; Liversidge, G.G. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res., 1996, 13, 272-78.
5. Amidon, G.L.; Lennernas, H.; Shah, V.P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 1995, 12, 413-20.
6. Tong, W.Q.; Whitesell, G. In situ salt screening-a useful technique for discovery support and preformulation studies. Pharm. Dev. Technol., 1998, 3, 215-23.
7. Bowker, M.J.; Bastine, R.J.; Slater, B.J. Salt selection and optimisation procedures for pharmaceutical new chemical entities. Org. Proc. Res. Dev., 2000, 4, 427-35.
8. Berge, S.M.; Bighley, L.D.; Monkhouse, D.C. Pharmaceutical salts. J. Pharm. Sci., 1977, 66, 1-19.
9. Yalkowsky, S.H.; Machatha, S. G.; Sanghvi, T. Structure determination and characterization of carbendazim hydrochloride dihydrate. AAPS Pharm. Sci. Tech., 2005, 06, E115-E119.
10. Caturla, F.; Amat, M.; Reinoso, R.F.; Cordoba, M.; Warrellow, G. racemic and chiral sulfoxides as potential prodrugs of 4-pyrone COX-2 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 3605-08.
11. Chemburkar, S.R.; Bauer, J.; Deming, K.; Spiwek, H.; Patel, K.; Morris, J.; Henry, R.; Spanton, S.; Dziki, W.; Porter, W.; Quick, J.; Bauer, P.; Donaubauer, J.; Narayanan, B. A.; Soldani, M.; Riley, D.; McFarland, K. Dealing with the Impact of ritonavir polymorphs on the late stages of bulk drug process development. Org. Proc. Res. Dev., 2000, 4, 413-17.
12. Miller, J.M.; Collman, B. M.; Greene, L.R.; Grant, D. J.W.; Blackburn, A.C. Identifying the stable polymorph early in the drug discovery-development process. Pharm. Dev. Tech., 2005, 10, 291-97.
13. Wermuth, C.G. In; Drug Design: Fact or Fantasy? Academic Press, London, 1984.
14. Brahmankar, D.M.; Jaiswal, S.B. In: Biopharmaceutics and Pharmacokinetics a Treatise, Vallabh Prakashan, New Delhi, 2002.
15. Yata, N.; Wu, W.M.; Yamajo, R.; Murakami, T.; Higashi, Y.; Higuchi, T. Enhanced rectal absorption of sodium ampicillin by N-acyl derivatives of collagen peptide in rabbits and rats. J. Pharm. Sci., 1984, 74, 1058-61.
16. Nudelman, A.; Rephaeli, A. Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity. J. Med. Chem., 2000, 43, 2962-66.
17. Bansal, A. K.; Kakumanu, V.K.; Arora, V. Investigation of factors responsible for low oral bioavailability of cefpodoxime proxetil. Int. J. Pharm., 2006, 317, 155-60.
18. Gladys, E.; Granero, A.; Amidon, G.L. Stability of valacyclovir: Implications for its oral bioavailability. Int. J. Pharm., 2006, 317, 14-18.
19. Albert, A. Chemical aspects of selective toxicity. Nature, 1958, 182, 421-23.
20. Harper, N.J. Drug Latentiation. J. Med. Pharm. Chem., 1958,1, 467-500
21. Jinyoung, K.; Youngshim, L.; Hojung, K.; Seock-Yong, K.; Kwang-Su, P.; Jun-Ho, C.; Yun-Yeong., L.; Byeong-Soo, K.; Yoongho, L.; Youhoon, C. Synthesis of naringenin amino acid esters as potential CDK2 Inhibitors. Bull. Korean Chem. Soc., 2005, 26, 2065-68.
22. Kyoung, K.; Kwang-su, P.; Woon-seok, Y.; Hyunah, C.; Youhoon, C. In vitro solubility, stability and permeability of novel quercetin-amino acid conjugates. Biol. Med. Chem., 2009, 17, 1164-71.